RSPO3 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, ICC, E |
---|---|
Primary Accession | Q9BXY4 |
Other Accession | NP_116173, 18490982 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | Predicted: 30 kDa Observed: 30 kDa |
Application Notes | RSPO3 antibody can be used for detection of RSPO3 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunocytochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL. |
Gene ID | 84870 |
---|---|
Target/Specificity | RSPO3; RSPO3 antibody is human and mouse reactive. At least three isoforms of RSPO3 are known to exist; this antibody will detect all three. |
Reconstitution & Storage | RSPO3 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. |
Precautions | RSPO3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RSPO3 |
---|---|
Synonyms | PWTSR, THSD2 |
Function | Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors, which acts as a key regulator of angiogenesis. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non- canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway (PubMed:21727895, PubMed:21909076, PubMed:22615920). Acts as a key regulator of angiogenesis by controlling vascular stability and pruning: acts by activating the non-canonical Wnt signaling pathway in endothelial cells (By similarity) (PubMed:21727895, PubMed:21909076, PubMed:22615920). Can also amplify Wnt signaling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3 (PubMed:29769720). |
Cellular Location | Secreted {ECO:0000250|UniProtKB:Q2TJ95}. |
Tissue Location | Ubiquitously expressed. Expressed at higher level in placenta, small intestine, fetal thymus and lymph node (PubMed:12463421). Highly expressed in endothelial cells (PubMed:26766444). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
RSPO3 is a member of the R-spondin family and plays a role in the regulation of Wnt (wingless-type MMTV integration site family)/beta-catenin and Wnt/planar cell polarity (PCP) signaling pathways, which are involved in development, cell growth and disease pathogenesis (1,2). RSPO3 has been shown to be involved in regulating the balance between angioblast and blood cell specification during embryonic vasculogenesis and angiogenesis and may be involved in tumor development (3,4).
References
Chen JZ, Wang S, Tang R, et al. Cloning and identification of a cDNA that encodes a novel human protein with thrombospondin type I repeat domain, hPWTSR. Mol. Biol. Rep. 2002; 29:287-92.
Kim KA, Wagle M, Tran K, et al. R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol. Biol. Cell 2008; 19:2588-96.
Kazanskaya O, Ohkawara B, Heroult M, et al. The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development. Development 2008; 3655-64.
Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488:660-4.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.